{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Delcath Systems, Inc."},"Symbol":{"label":"Symbol","value":"DCTH"},"Address":{"label":"Address","value":"1633 BROADWAY,SUITE 22C, NEW YORK, New York, 10019, United States"},"Phone":{"label":"Phone","value":"+1 212 489-2100"},"Industry":{"label":"Industry","value":"Medical/Dental Instruments"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects."},"CompanyUrl":{"label":"Company Url","value":"https://www.delcath.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Gerard J. Michel","title":"President, Chief Executive Officer & Director"},{"name":"Johnny John","title":"Senior VP-Clinical Development & Medical Affairs"},{"name":"Martha S. Rook","title":"Chief Operating Officer"},{"name":"Vojislav Vukovic","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}